182 related articles for article (PubMed ID: 28183256)
1. Current and Emerging Treatments for Metastatic Renal Cell Carcinoma.
Cavaliere C; D'Aniello C; Pepa CD; Pisconti S; Berretta M; Facchini G
Curr Cancer Drug Targets; 2018; 18(5):468-479. PubMed ID: 28183256
[TBL] [Abstract][Full Text] [Related]
2. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.
Alimohamed N; Lee JL; Srinivas S; Bjarnason GA; Knox JJ; Mackenzie MJ; Wood L; Vaishampayan UN; Tan MH; Rha SY; Donskov F; Tantravahi S; Kollmannsberger C; North S; Rini BI; Choueiri TK; Heng DY
Clin Genitourin Cancer; 2014 Aug; 12(4):e127-31. PubMed ID: 24485801
[TBL] [Abstract][Full Text] [Related]
3. Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma.
Zarrabi K; Wu S
Curr Oncol Rep; 2018 Apr; 20(5):41. PubMed ID: 29611002
[TBL] [Abstract][Full Text] [Related]
4. Treatment of elderly patients with metastatic renal cell carcinoma.
Zanardi E; Grassi P; Cavo A; Verzoni E; Maggi C; De Braud F; Boccardo F; Procopio G
Expert Rev Anticancer Ther; 2016; 16(3):323-34. PubMed ID: 26654225
[TBL] [Abstract][Full Text] [Related]
5. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase inhibitors in renal cell carcinoma.
Daste A; Grellety T; Gross-Goupil M; Ravaud A
Expert Opin Pharmacother; 2014 Feb; 15(3):337-51. PubMed ID: 24328606
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies: another option for metastatic RCC.
Hutchinson L
Nat Rev Clin Oncol; 2013 Nov; 10(11):607. PubMed ID: 24061041
[No Abstract] [Full Text] [Related]
8. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
Oudard S; Elaidi RT
Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
[TBL] [Abstract][Full Text] [Related]
9. Advanced renal cell carcinoma: current and emerging management strategies.
Escudier B
Drugs; 2007; 67(9):1257-64. PubMed ID: 17547470
[TBL] [Abstract][Full Text] [Related]
10. Non-clear cell renal cell carcinoma, part 2: therapy.
Valenca LB; Hirsch MS; Choueiri TK; Harshman LC
Clin Adv Hematol Oncol; 2015 Jun; 13(6):383-91. PubMed ID: 26352894
[TBL] [Abstract][Full Text] [Related]
11. Current systemic management of metastatic renal cell carcinoma - first line and second line therapy.
Wright I; Kapoor A
Curr Opin Support Palliat Care; 2011 Sep; 5(3):211-21. PubMed ID: 21725244
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort.
Iacovelli R; Cartenì G; Sternberg CN; Milella M; Santoni M; Di Lorenzo G; Ortega C; Sabbatini R; Ricotta R; Messina C; Lorusso V; Atzori F; De Vincenzo F; Sacco C; Boccardo F; Valduga F; Massari F; Baldazzi V; Cinieri S; Mosca A; Ruggeri EM; Berruti A; Cerbone L; Procopio G
Eur J Cancer; 2013 Jun; 49(9):2134-42. PubMed ID: 23518211
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
[TBL] [Abstract][Full Text] [Related]
14. Metastatic clear cell renal carcinoma - an unusual response to Temsirolimus in second line therapy.
Stanculeanu DL; Lazescu A; Zob DD; Bunghez R; Anghel R; Poteca TD
J Med Life; 2016; 9(2):193-8. PubMed ID: 27453754
[TBL] [Abstract][Full Text] [Related]
15. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
[TBL] [Abstract][Full Text] [Related]
16. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
17. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.
Ferté C; Koscielny S; Albiges L; Rocher L; Soria JC; Iacovelli R; Loriot Y; Fizazi K; Escudier B
Eur Urol; 2014 Apr; 65(4):713-20. PubMed ID: 23993162
[TBL] [Abstract][Full Text] [Related]
18. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
[TBL] [Abstract][Full Text] [Related]
19. Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers.
Castellano D; Ravaud A; Schmidinger M; De Velasco G; Vazquez F
Cancer Treat Rev; 2013 May; 39(3):230-40. PubMed ID: 22647546
[TBL] [Abstract][Full Text] [Related]
20. Use of targeted therapies for advanced renal cell carcinoma in the Asia-Pacific region: opinion statement from China, Japan, Taiwan, Korea, and Australia.
Ye D; Eto M; Chung JS; Kimura G; Chang WC; Chang YH; Pang ST; Lee JL; Niu Y; Gurney H; Uemura H
Clin Genitourin Cancer; 2014 Aug; 12(4):225-33. PubMed ID: 24630778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]